Tags: spms + drugs.with.MS

Sort by: Date / Title / URL

1. Rebif - multiple sclerosis encyclopaedia
   Here is a table of clinical trials of Rebif.
   13-07-2007 to clinical trial, drug company, drugs, rebif, relapsing remitting, spms by admin
2. BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
   the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
   07-06-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, spms by admin
3. BioMS Medical Announces Lead Investigator In United States Phase III Multiple Sclerosis Trial
   BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Clyde E. Markowitz as the lead investigator in the United States for the Company’s pivotal phase III clinical trial of its lead dru
   28-04-2007 to canada, drug company, drugs, mbp8298, multiple sclerosis, spms by admin
4. BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
   BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
   05-03-2007 to drug company, drugs, mbp8298, multiple sclerosis, spms, treatment by admin
5. BioMS - Clinical Trial Information for MBP8298
   A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis
   14-08-2006 to clinical trial, drug company, drugs, mbp8298, multiple sclerosis, spms by admin
6. BioMS Medical Announces Second Quarter 2006 Results
   More than 300 patients enrolled in pivotal phase II/III multiple sclerosis trial
   14-08-2006 to canada, clinical trial, drug company, drugs, multiple sclerosis, spms by admin
7. Cambridge Antibody - ABT-874
   ABT-874 is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
   30-07-2006 to abt-874, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, rrms, spms, treatment by admin
8. Campath-1H - multiple sclerosis encyclopaedia
   In one small trial of 27 people with Secondary Progressive MS (SPMS), the drug was found to virtually eliminate the formation of new lesions and the inflammation associated with the disease for at least eighteen months.
   22-07-2006 to campath, drugs, multiple sclerosis, research, spms, treatment by admin
9. National MS Society | Novantrone (Mitoxantrone)
   Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in MS, it was used only to treat certain forms of cancer. It acts in MS by suppressing the activity of T cells, B cells, and macrophages that are th
   21-07-2006 to drugs, mitoxantrone, multiple sclerosis, prms, rrms, spms, treatment by admin
10. Final Results For ReceptoPharm's RPI-78M In Multiple Sclerosis Animal Model, Nutra Pharma
    EAE (experimental allergic encephalomyelitis) is the standard benchmark animal methodology for the study of MS. ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease
    28-06-2006 to drug company, drugs, multiple sclerosis, ppms, primary progressive, relapsing remitting, rrms, spms by admin
11. BioMS Medical expands pivotal multiple sclerosis trial into The Netherlands
    BioMS Medical Corp (TSX: MS), a leadingdeveloper in the treatment of multiple sclerosis (MS), today announced it hasreceived approval to start patient enrolment in The Netherlands for itspivotal phase II/III clinical trial of MBP8298, a proprietary synthe
    22-06-2006 to drug company, drugs, multiple sclerosis, research, spms, treatment by admin

First / Previous / Next / Last / Page 1 of 1